May 29, 2025 7:00 am EDT Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025
Apr 21, 2025 7:00 am EDT Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
Mar 19, 2025 7:45 am EDT Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
Mar 18, 2025 4:32 pm EDT Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
Feb 06, 2025 6:30 am EST Immunovant Reports Financial Results for the Quarter Ended December 31, 2024
Nov 07, 2024 6:30 am EST Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024
Oct 29, 2024 6:30 am EDT Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting